Aim to assess the activity of superoxide dismutase in erythrocytes of rats after a single intramuscular injection of naphazoline in radiofrequency dose and in experimental simulation of acute radiation sickness. Material and methods. The activity of erythrocytes superoxide dismutase (SOD) after single intramuscular injection of nafazoline in experimental modeling of acute radiation sickness was investigated. The pharmacological properties and mechanisms of radioprotective action of nafazoline were clarified based on the dynamics of activity of erythrocytes SOD in intact and irradiated animals with the dose of 7,4 Gy. Results. The superoxide dismutase activity was found to increase significantly 60 min after single intramuscular administration of nafazolin at a dose of 5 mg/kg. Under experimental conditions of acute radiation disease modeling, a decrease in superoxide dismutase activity was observed within the first hour after exposure, evidencing the direct involvement of the antioxidant system components in the inactivation of free-radical reaction products. Conclusion. The radioprotective properties of naphazoline may be due not only to reduction of oxygen delivery to the cells of radiosensitive tissues and inhibition of their metabolism by effect on 2-adreno- and imidazoline receptors, but also by activation of antioxidant system links.

INTRODUCTION: TDespite the achievements of the modern medicine, use of some medical drugs (MDs) is associated with both the absence of a significant therapeutic effect due to peculiarities of the physico-chemical interaction in the internal environment of an organism, and with the adverse effect on organs and tissues. The advanced technologies of creation of micro- and nanoparticles will permit to improve pharmacokinetics and pharmacodynamics of the drug, its bioavailability and solubility, the ability of crossing blood-brain barriers, and to reduce undesirable systemic effects. MDs using micro- and nanoparticles, have a targeted effect on the focus of pathological lesion. An important additional advantage is a possibility of using micro- and nanoparticles in development of long-acting MDs. The main active substances immobilized to micro- and nanoparticles, open up new prospects for effective treatment of different pathological conditions (neoplasms, diseases of cardiovascular and central nervous system, inflammatory processes, wounds), and for realization of new imaging capabilities in foci of a pathological process, which is especially important in diagnostic procedures. CONCLUSION: The article presents a summary of the ideas of methods of micro- and nanoencapsulation, and assessments of the prospects for the development of drugs for the correction of pathological conditions using innovative technologies.

Samples of antiemetic drugs (ondansetronum, palonosetronum, metoclopramidum) in the form of powder for inhalation have been developed by the method of spray drying. The granulometric composition, hygroscopicity and aerodynamic distribution of aerosol particles of the drugs have been investigated. The dosage form of the powder for inhalation of antiemetics (ondansetronum and palonosetronum) in terms of its particle size distribution, hygroscopicity and content of the agent corresponds to those for inhalation using dry powder inhalers. In the study of the phase-dispersed composition of aerosol, ondansetronum and palonosetronum in the dosage form of powder for inhalation as part of the HandiHaler inhaler (at a flow rate of 60 l / min) showed high rates of the released dose up to 72-76%, respirable particle fraction (up to 5 m) up to 54 -56% and a mass median particle size of about 3 microns. Obtaining the inhaled form of metoclopramide requires optimization of the production method for receiving the product with acceptable pharmaceutical properties.